prostate cancer and li-fraumeni syndrome: implications for screening and therapy

Clicks: 250
ID: 223225
2015
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #20 of 71 articles by views in advances in human-computer interaction

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Li-Fraumeni Syndrome (LFS) is an autosomal dominant genetic disorder associated with mutations in the TP53 gene and characterized by a propensity to develop a variety of malignancies resulting in a shortened lifespan. We report a case of prostate cancer in a 50 year old male with LFS. Experimental studies suggest that TP53 mutations in prostate cancer are associated with therapeutic resistance to radiation, chemotherapy, and anti-androgens, implying that LFS men may experience more aggressive cancer biology with implications for therapeutic decisions. The potential of prostate cancer to develop earlier in LFS favors institution of screening at earlier ages.
Reference Key
spees2015urologyprostate Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Colleen K. Spees;Kelly J. Kelleher;Ronney Abaza;Steven K. Clinton
Journal advances in human-computer interaction
Year 2015
DOI
10.1016/j.eucr.2015.01.002
URL
http://www.sciencedirect.com/science/article/pii/S2214442015000030
Keywords
p53 li-fraumeni syndrome tp53 urology

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.